CGT Regulatory Flexibility and Global Harmonization

The FDA’s January 11, 2026 guidance on more flexible CMC approaches for cell and gene therapies, and EMA’s investigational ATMP (Advanced Therapy Medicinal Product) guideline effective July 1, 2025, are cornerstone references for designing phase-appropriate controls, potency assays, comparability plans and global dossier strategies. At Pharmefex, we are actively monitoring and continue to highlight these developments for the community.

We can see that regulators are adapting to the realities of CGT development. The FDA’s 2026 communication makes clear that, when scientifically justified, it will allow greater flexibility in clinical development plans, commercial specifications and process- validation protocols. That matters because many CGT programs serve small patient populations, work on compressed timelines and see their manufacturing processes evolve as science advances. To foster earlier dialogue, FDA also points sponsors to its CMC Development and Readiness Pilot (CDRP), which accelerates reviewer engagement for fast-track programs.

Similarly, EMA’s investigational ATMP guideline has become a key reference for CGT developers in Europe, providing clear expectations for phase-appropriate controls, potency assays, manufacturing changes, and comparability throughout development. The guideline clarifies how requirements evolve as programs mature, reinforcing the importance of potency, process understanding, and comparability planning. For sponsors, it offers a practical roadmap for building global CMC strategies that support EU clinical trials and eventual worldwide registration. 

This increased flexibility adds complexity, as both FDA and EMA increasingly expect sponsors to justify CMC decisions early and rigorously, often with different areas of emphasis.

At Pharmefex, we’ve been reporting on this previously and are tracking and amplifying these CGT CMC updates because they’re central to our work. We help teams define phase-appropriate CMC roadmaps, plan comparability studies or validation work up front, prepare for FDA and EMA interactions, and identify gaps before they become costly.

#CMC #CellTherapy #GeneTherapy #ATMP #RegulatoryStrategy #Biotech #Pharma #Pharmefex

Key sources: • FDA CGT CMC Flexibilities: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/flexible-requirements-cell-and-gene-therapies-advance-innovation 

• FDA CDRP Program: https://www.fda.gov/drugs/pharmaceutical-quality-resources/chemistry-manufacturing-and-controls-development-and-readiness-pilot-cdrp-program 

• EMA Investigational ATMP Guideline: https://www.ema.europa.eu/en/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials-scientific-guideline